Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2024-12-05 00:00:00 ET · period of report 2024-12-03 · accession 0001415889-24-028431 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-12-05 | 2024-12-03+ | KNSA | Ragosa Mark | CFO | M - OptEx | $10.76 | +15.1K | 24.1K | +169% | +$162.6K |
| DM | 2024-12-05 | 2024-12-03+ | KNSA | Ragosa Mark | CFO | S - Sale+OE | $21.37 | -15.1K | 23.0K | -40% | -$323.0K |
| DM | 2024-12-05 | 2024-12-03+ | KNSA | Ragosa Mark | CFO | M - OptEx | $0.00 | -15.1K | 33.1K | -31% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Share | 2024-12-04 | M | A | 5,024 | $10.76 | 27,982 | D | — | — | |
| 2 | Common | Class A Ordinary Share | 2024-12-03 | M | A | 8,969 | $10.76 | 31,927 | D | — | — | |
| 3 | Common | Class A Ordinary Share | 2024-12-03 | S | D | 8,969 | $21.45 | 22,958 | D | — | — | (F2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.26 and $21.70. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |
| 4 | Common | Class A Ordinary Share | 2024-12-05 | S | D | 1,123 | $21.25 | 22,958 | D | — | — | (F4) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.25 and $21.265. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |
| 5 | Common | Class A Ordinary Share | 2024-12-04 | S | D | 5,024 | $21.25 | 22,958 | D | — | — | (F3) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.25 and $21.265. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |
| 6 | Common | Class A Ordinary Share | 2024-12-05 | M | A | 1,123 | $10.76 | 24,081 | D | — | — | |
| 7 | Derivative | Share Option | 2024-12-05 | M | D | 1,123 | $0.00 | 26,934 | D | $10.76 · — to 2033-03-31 | 1,123 Class A Ordinary Shares | (F5) The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 2, 2023. |
| 8 | Derivative | Share Option | 2024-12-04 | M | D | 5,024 | $0.00 | 28,057 | D | $10.76 · — to 2033-03-31 | 5,024 Class A Ordinary Share | (F5) The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 2, 2023. |
| 9 | Derivative | Share Option | 2024-12-03 | M | D | 8,969 | $0.00 | 33,081 | D | $10.76 · — to 2033-03-31 | 8,969 Class A Ordinary Share | (F5) The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 2, 2023. |